Iterum Therapeutics plc (ITRM)
| Market Cap | 23.18M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -35.58M |
| Shares Out | 16.55M |
| EPS (ttm) | -2.65 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 111,201 |
| Open | 1.440 |
| Previous Close | 1.410 |
| Day's Range | 1.400 - 1.490 |
| 52-Week Range | 0.622 - 2.500 |
| Beta | 2.32 |
| Analysts | Strong Buy |
| Price Target | 6.00 (+317.25%) |
| Earnings Date | May 13, 2024 |
About ITRM
Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and intravenous formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland. [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to one analyst, the rating for ITRM stock is "Strong Buy" and the 12-month stock price forecast is $6.0.
News
Iterum Therapeutics Reports First Quarter 2024 Financial Results
- -NDA Resubmitted; FDA Action Expected in Early Q4 24-- - -Cash Runway into 2025, including through Potential FDA Approval--
Iterum Therapeutics to Report First Quarter 2024 Financial Results on May 13, 2024
DUBLIN, Ireland and CHICAGO, May 06, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral a...
Iterum Therapeutics Resubmits New Drug Application to U.S. Food and Drug Administration for Oral Sulopenem
--First Oral Penem in the U.S. and Second New Oral Treatment for uUTIs in Over 25 Years, if approved-- --Potential Approval Early Q4 2024--
Iterum Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
- -Resubmission of NDA On Track for Early Q2 24— - -Cash Runway into 2025, including through Potential FDA Approval in Early Q4 24-- --Company to host conference call today at 8:30amET-- DUBLIN, Irela...
Iterum Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 28, 2024
DUBLIN, Ireland and CHICAGO, March 21, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral...
Iterum Therapeutics to Participate in H.C. Wainwright Virtual @Home Fireside Chat
DUBLIN, Ireland and CHICAGO, March 15, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (Iterum), a clinical-stage pharmaceutical company focused on developing next-generation oral anti...
Iterum Therapeutics Announces Positive Topline Results from its Phase 3 REASSURE Clinical Trial of Oral Sulopenem in Uncomplicated Urinary Tract Infections
Phase 3 REASSURE Trial Met Primary Endpoint of Non-Inferiority to Augmentin ® ; Demonstrated Statistical Superiority Re-submission of NDA to FDA Expected in Q2 2024 Potential to be First Oral Penem Ap...
Iterum Therapeutics Regains Compliance with Nasdaq Bid Price Rule
DUBLIN, Ireland and CHICAGO, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company”), a clinical-stage pharmaceutical company focused on developing next generation ora...
Iterum Therapeutics Reports Third Quarter 2023 Financial Results
-- Top-line Data for Pivotal REASSURE Trial Expected in Early Q1 2024 – --Resubmission of NDA for uUTI Expected in Q2 2024- - DUBLIN, Ireland and CHICAGO, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Iterum Ther...
Iterum Therapeutics to Provide Business Update and Report Third Quarter 2023 Financial Results on November 14, 2023
DUBLIN, Ireland and CHICAGO, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral ...
Iterum Therapeutics to Present Data at IDWeek 2023
DUBLIN, Ireland and CHICAGO, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral ...
Iterum Therapeutics Reports Second Quarter 2023 Financial Results
-- Expect to Complete Enrollment in Q1 2024; Topline Data Expected in Q2 2024 -- -- Cash Runway into Q3 2024-- DUBLIN, Ireland and CHICAGO, Aug. 11, 2023 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (N...
Iterum Therapeutics to Provide Business Update and Report Second Quarter 2023 Financial Results on August 11, 2023
DUBLIN, Ireland and CHICAGO, Aug. 04, 2023 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral ...
Iterum Therapeutics to Present Data at ASM Microbe 2023
DUBLIN, Ireland and CHICAGO, June 12, 2023 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral ...
Iterum Therapeutics Reports First Quarter 2023 Financial Results
--Registration Trial for uUTI Ongoing and On Track-- --Cash Runway until Mid-2024-- DUBLIN, Ireland and CHICAGO, May 12, 2023 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (Iterum), a cli...
Iterum Therapeutics Presents Scientific Posters at ECCMID 2023 Highlighting Application of Desirability of Outcomes Ranking (DOOR) to two Registration Trials
DUBLIN, Ireland and CHICAGO, April 20, 2023 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral...
Iterum Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results
- -Registration Trial for uUTI Ongoing and On Track- - - -Cash Runway until Mid-2024-- --Company to host conference call today at 8:30amET--
Iterum Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2022 Financial Results on March 16, 2023
DUBLIN, Ireland and CHICAGO, March 09, 2023 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral...
Iterum Therapeutics Reports Employment Inducement Grant
DUBLIN, Ireland and CHICAGO, Jan. 11, 2023 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (“Iterum Therapeutics”), a clinical-stage pharmaceutical company focused on developing next genera...
Iterum Therapeutics announces Issuance of Allowance for a U.S. Patent Covering Oral Sulopenem
DUBLIN, Ireland and CHICAGO, Dec. 15, 2022 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company” or “Iterum”), a clinical-stage pharmaceutical company focused on developing next ge...
Iterum Therapeutics Reports Third Quarter 2022 Financial Results
--Patient Enrollment in Registration Trial for uUTI Underway-- --Cash Runway into 2024--
Iterum Announces First Patient Dosed in REASSURE, a Phase 3 Clinical Trial of Oral Sulopenem in Uncomplicated Urinary Tract Infections
-- NDA resubmission expected in Second Half of 2024, if successful-- --Oral sulopenem, if approved, could be the first antibiotic approved for uncomplicated urinary tract infections in over 25 years--
Iterum Therapeutics to Present Data at IDWeek 2022
DUBLIN, Ireland and CHICAGO, Oct. 17, 2022 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral ...
Iterum Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference
DUBLIN, Ireland and CHICAGO, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral...
Iterum Therapeutics Announces Date of 1-for-15 Reverse Share Split
DUBLIN, Ireland and CHICAGO, Aug. 16, 2022 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company”), a clinical-stage pharmaceutical company focused on developing next generation ora...